Fetal/Neonatal Allo-Immune Thrombocytopenia (FNAIT): Past, Present, and Future
- 1 April 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Obstetrical & Gynecological Survey
- Vol. 63 (4), 239-252
- https://doi.org/10.1097/ogx.0b013e31816412d3
Abstract
We reviewed the English, American, and German literature for articles describing the prevalence, clinical presentation, outcome, therapeutic options, and screening possibilities for fetal/neonatal allo-immune thrombocytopenia (FNAIT), published between January 1950 and March 2007. The reported prevalence of FNAIT in human platelet antigen (HPA)-1a-negative women varies between 1/600 to 1/5000 live births among various populations. The typical picture is that of a neonate presenting with purpura minutes to hours after birth, born to a healthy mother with no history of infection or abnormal bleeding, after an uneventful pregnancy with a normal maternal platelet count. Thrombocytopenia in FNAIT can be severe, with intracranial hemorrhage occurring in 10% to 30% of severe FNAIT cases. Several types of neonatal treatment have been proposed, of which transfusion of HPA-compatible platelets is most effective. Antenatal management of FNAIT consists of weekly maternal intravenous immunoglobulin (IVIG) infusions, with or without oral steroid therapy. Serial fetal platelet transfusions can be provided in cases of failure of IVIG therapy, but the multiple cordocenteses that would be required to administer the platelets entail substantial risk. The possibilities for antenatal screening of first pregnancies are limited. Postnatal screening does not prevent neonatal morbidity and mortality. TARGET AUDIENCE: Obstetricians & Gynecologists, Family Physicians. LEARNING OBJECTIVES: After completion of this article, the reader should be able to summarize the many and varied causes of neonatal thrombocytopenia, explain that fetal/neonatal allo-immune thrombocytopenia (FNAIT) is a rare but devastating cause with potential high risk of recurrence, and recall the treatment options for FNAIT as well as their potential side effectsKeywords
This publication has 131 references indexed in Scilit:
- Alloimmune thrombocytopenia: State of the art 2006American Journal of Obstetrics and Gynecology, 2006
- Frequencies of maternal platelet alloantibodies and autoantibodies in suspected fetal/neonatal alloimmune thrombocytopenia, with emphasis on human platelet antigen‐15 alloimmunizationVox Sanguinis, 2005
- Alloimmune thrombocytopenia of the fetus and the newbornBlood Reviews, 2002
- Neonatal alloimmune thrombocytopenia due to anti‐HPA 1a antibodies; the level of maternal antibodies predicts the severity of thrombocytopenia in the newbornBJOG: An International Journal of Obstetrics and Gynaecology, 2000
- Intraventricular haemorrhage and its prognosis, prevention and treatment in term infantsJournal of Tropical Pediatrics, 1999
- Perinatal intracranial hemorrhage due to severe neonatal alloimmune thrombocytopenic purpura (NAITP) associated with anti-Yukb (HPA-4a) antibodiesBrain & Development, 1995
- Antenatal Diagnosis and Management of Fetomaternal Alloimmune ThrombocytopeniaAmerican Journal of Perinatology, 1995
- Induction of additional red cell alloantibodies after intrauterine transfusionsTransfusion, 1994
- HLA-DRw52a is involved in alloimmunization against PL-A1 antigenHuman Immunology, 1990
- Antenatal Treatment of Neonatal Alloimmune ThrombocytopeniaNew England Journal of Medicine, 1988